Literature DB >> 16245279

Prostate cancer and genetic susceptibility: a genome scan incorporating disease aggressiveness.

Janet L Stanford1, Shannon K McDonnell, Danielle M Friedrichsen, Erin E Carlson, Suzanne Kolb, Kerry Deutsch, Marta Janer, Lee Hood, Elaine A Ostrander, Daniel J Schaid.   

Abstract

BACKGROUND: Prostate cancer is a heterogeneous disease, both genetically and phenotypically. Linkage studies attempting to map genes for hereditary prostate cancer (HPC) have proved challenging, and one potential problem contributing to this challenge is the variability in disease phenotypes.
METHODS: We collected clinical data on 784 affected men with prostate cancer from 248 HPC families for whom a genomic screen was performed. Disease characteristics (i.e., Gleason score, stage, prostate-specific antigen (PSA)) were used to classify affected men into categories of clinically insignificant, moderate, or aggressive prostate cancer. To potentially enrich for a genetic etiology, we restricted linkage analyses to only men with aggressive disease, although we used genotype information from all family members; linkage analyses used both dominant and recessive models. In addition, subset analyses considered age at diagnosis, number of affected men per family and other stratifications to try to increase genetic homogeneity.
RESULTS: Several regions of interest (heterogeneity LOD score, HLOD>1.0) were identified in families (n=123) with >or=2 affecteds with aggressive prostate cancer. "Suggestive" linkage was observed at chromosome 22q11.1 (Dominant model HLOD=2.18) and the result was stronger (Dominant HLOD=2.75) in families with evidence of male-to-male transmission. A second region at 22q12.3-q13.1 was also highlighted (Recessive model HLOD=1.90) among men with aggressive disease, as was a region on chromosome 18.
CONCLUSIONS: These analyses suggest that using clinically defined phenotypes may be a useful approach for simplifying the locus heterogeneity problems that confound the search for prostate cancer susceptibility genes. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16245279     DOI: 10.1002/pros.20349

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  27 in total

1.  Genetic variants and prostate cancer risk: candidate replication and exploration of viral restriction genes.

Authors:  Joan P Breyer; Kate M McReynolds; Brian L Yaspan; Kevin M Bradley; William D Dupont; Jeffrey R Smith
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06-30       Impact factor: 4.254

Review 2.  Prostate cancer susceptibility loci: finding the genes.

Authors:  Elanie A Ostrander; Bo Johannesson
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

3.  Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry.

Authors:  Prodipto Pal; Huifeng Xi; Saurav Guha; Guangyun Sun; Brian T Helfand; Joshua J Meeks; Brian K Suarez; William J Catalona; Ranjan Deka
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

4.  Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.

Authors:  Brian T Helfand; Kimberly A Roehl; Phillip R Cooper; Barry B McGuire; Liesel M Fitzgerald; Geraldine Cancel-Tassin; Jean-Nicolas Cornu; Scott Bauer; Erin L Van Blarigan; Xin Chen; David Duggan; Elaine A Ostrander; Mary Gwo-Shu; Zuo-Feng Zhang; Shen-Chih Chang; Somee Jeong; Elizabeth T H Fontham; Gary Smith; James L Mohler; Sonja I Berndt; Shannon K McDonnell; Rick Kittles; Benjamin A Rybicki; Matthew Freedman; Philip W Kantoff; Mark Pomerantz; Joan P Breyer; Jeffrey R Smith; Timothy R Rebbeck; Dan Mercola; William B Isaacs; Fredrick Wiklund; Olivier Cussenot; Stephen N Thibodeau; Daniel J Schaid; Lisa Cannon-Albright; Kathleen A Cooney; Stephen J Chanock; Janet L Stanford; June M Chan; John Witte; Jianfeng Xu; Jeannette T Bensen; Jack A Taylor; William J Catalona
Journal:  Hum Genet       Date:  2015-02-26       Impact factor: 4.132

5.  Genome-wide linkage scan for prostate cancer susceptibility genes in men with aggressive disease: significant evidence for linkage at chromosome 15q12.

Authors:  Ethan M Lange; Lindsey A Ho; Jennifer L Beebe-Dimmer; Yunfei Wang; Elizabeth M Gillanders; Jeffrey M Trent; Leslie A Lange; David P Wood; Kathleen A Cooney
Journal:  Hum Genet       Date:  2006-03-01       Impact factor: 4.132

Review 6.  The genetics of cancer risk.

Authors:  Mark M Pomerantz; Matthew L Freedman
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

7.  A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study).

Authors:  Ali S Murad; George Davey Smith; Sarah J Lewis; Angela Cox; Jenny L Donovan; David E Neal; Freddie C Hamdy; Richard M Martin
Journal:  Int J Mol Epidemiol Genet       Date:  2010-04-01

8.  Genome-wide linkage scan of prostate cancer Gleason score and confirmation of chromosome 19q.

Authors:  Daniel J Schaid; Janet L Stanford; Shannon K McDonnell; Miia Suuriniemi; Laura McIntosh; Danielle M Karyadi; Erin E Carlson; Kerry Deutsch; Marta Janer; Lee Hood; Elaine A Ostrander
Journal:  Hum Genet       Date:  2007-05-08       Impact factor: 4.132

Review 9.  The role of the BRCA2 gene in susceptibility to prostate cancer revisited.

Authors:  Elaine A Ostrander; Miriam S Udler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

10.  Fine mapping of familial prostate cancer families narrows the interval for a susceptibility locus on chromosome 22q12.3 to 1.36 Mb.

Authors:  Bo Johanneson; Shannon K McDonnell; Danielle M Karyadi; Scott J Hebbring; Liang Wang; Kerry Deutsch; Laura McIntosh; Erika M Kwon; Miia Suuriniemi; Janet L Stanford; Daniel J Schaid; Elaine A Ostrander; Stephen N Thibodeau
Journal:  Hum Genet       Date:  2007-12-08       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.